## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.6% below STRENGTH zone (4.0-10.0%); PEG 1.71 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($69.46)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Curodont Drill-Free Caries Treatment to Be Distributed by Henry Schein Across U.S. Dental Market**
- Source: Orthodontic Products | 20251202T220656 | Bullish | Relevance: 100%
- Henry Schein Inc. announced an expanded agreement with vVARDIS to become the exclusive U.S. distributor of the Curodont Repair Fluoride Plus product across all dental market segments, effective January 1, 2026. This expansion builds on a previous agreement and extends Henry Schein's distribution rights to general dentistry, orthodontics, and pediatric dentistry practices nationwide. Curodont is a drill-free caries treatment for early-stage cavities, and this partnership aims to make it more accessible to the entire U.S. dental community given its success in reaching over 10% of U.S. dental offices.

**2. Henry Schein Inc. stock underperforms Tuesday when compared to competitors**
- Source: MarketWatch | 20251202T172300 | Somewhat-Bearish | Relevance: 100%
- Henry Schein Inc. (HSIC) stock fell 1.97% to $71.67 on Tuesday, underperforming the broader market which saw the S&P 500 Index (SPX) rise 0.25% and the Dow Jones Industrial Average (DJIA) gain 0.39%. This marks the fourth consecutive day of losses for the company's stock.

**3. HSIC Stock Benefits From Expanded Partnership With vVARDIS**
- Source: TradingView | 20251202T152143 | Bullish | Relevance: 100%
- Henry Schein, Inc. (HSIC) has expanded its partnership with vVARDIS, gaining exclusive U.S. distribution rights for the Curodont Repair Fluoride Plus product starting January 1, 2026. This move is expected to bolster HSIC's Dental business and maintain positive stock momentum, building on previous strategic collaborations. The drill-free Curodont product addresses early-stage cavities, tapping into a significant market opportunity and aligning with the company's commitment to advancing oral health.

**4. Henry Schein (Nasdaq: HSIC) to be exclusive US Curodont distributor across dental market**
- Source: Stock Titan | 20251201T213400 | Bullish | Relevance: 100%
- Henry Schein, Inc. has expanded its partnership with vVARDIS, gaining exclusive U.S. distribution rights for the Curodont™ Repair Fluoride Plus product across all dental market segments, effective January 1, 2026. This expansion builds on a previous agreement for Dental Service Organizations and will now cover general dentistry, orthodontics, and pediatric dentistry nationwide. Curodont™ is a drill-free, needle-free solution for early-stage cavities, addressing a significant unmet need in oral health.

**5. Henry Schein expands vVARDIS distribution deal for drill-free cavity treatment**
- Source: Investing.com | 20251201T164500 | Bullish | Relevance: 100%
- Henry Schein, Inc. has expanded its exclusive U.S. distribution agreement with vVARDIS for Curodont Repair Fluoride Plus, a drill-free cavity treatment, to include all dental market segments starting January 1, 2026. This expansion broadens their previous 2024 agreement which was limited to Dental Service Organizations, now extending to general dentistry, orthodontics, and pediatric dentistry nationwide. The move reflects Henry Schein's strengthening position in the dental supplies market and vVARDIS's success with the product, which has already been adopted by over 10% of U.S. dental offices.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-05 | JP Morgan | $78 | $76 | +3% |
| 2025-11-05 | Barrington Rese | $79 | $78 | +1% |
| 2025-11-05 | Morgan Stanley | $58 | $55 | +5% |
| 2025-11-05 | Wells Fargo | $76 | $70 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-05 | JP Morgan | main | Overweight |
| 2025-11-05 | Barrington Rese | main | Outperform |
| 2025-11-05 | Morgan Stanley | main | Underweight |
| 2025-11-05 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.6% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.71 elevated, pricing in significant growth expectations. Analyst sentiment positive (5 raises, avg +5%). Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 5.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.71 |
| Forward P/E | 13.8 |
| Current P/E | 14.8 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.0% to -1.6% (-6.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.55% (CS: 36) | Neutral |
| RSI_14 | 56.9 | Neutral |
| MACD Histogram | -0.22 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.074x | Above |
| vs SMA200 | 1.052x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $72.88
- **Stop Loss:** $69.46 (4.7% risk)
- **Target:** $76.30 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 277
- **Position Value:** $20,187.76
- **Portfolio %:** 20.19%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*